Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.68 - $0.97 $3,277 - $4,675
-4,820 Reduced 0.28%
1,737,208 $1.27 Million
Q4 2023

Feb 14, 2024

SELL
$0.72 - $1.13 $103,647 - $162,669
-143,955 Reduced 7.63%
1,742,028 $1.62 Million
Q2 2023

Aug 14, 2023

BUY
$2.15 - $3.16 $271,127 - $398,494
126,106 Added 7.17%
1,885,983 $4.05 Million
Q1 2023

May 15, 2023

BUY
$2.16 - $3.47 $1.14 Million - $1.84 Million
530,008 Added 43.09%
1,759,877 $4.95 Million
Q4 2022

Feb 14, 2023

SELL
$1.73 - $2.95 $451,088 - $769,197
-260,745 Reduced 17.49%
1,229,869 $2.77 Million
Q3 2022

Nov 14, 2022

BUY
$2.39 - $3.96 $3.56 Million - $5.9 Million
1,490,614 New
1,490,614 $3.56 Million
Q2 2022

Aug 15, 2022

SELL
$1.75 - $10.44 $22,599 - $134,822
-12,914 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$6.7 - $10.23 $2.66 Million - $4.06 Million
-396,401 Reduced 96.84%
12,914 $120,000
Q4 2021

Feb 14, 2022

BUY
$9.43 - $17.14 $2.94 Million - $5.34 Million
311,293 Added 317.57%
409,315 $3.9 Million
Q3 2021

Nov 15, 2021

BUY
$17.37 - $27.92 $1.7 Million - $2.74 Million
98,022 New
98,022 $1.75 Million
Q2 2021

Aug 16, 2021

SELL
$26.14 - $37.45 $2.8 Million - $4 Million
-106,941 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$23.5 - $39.58 $720,627 - $1.21 Million
-30,665 Reduced 22.28%
106,941 $2.88 Million
Q4 2020

Feb 16, 2021

SELL
$22.55 - $30.87 $690,413 - $945,146
-30,617 Reduced 18.2%
137,606 $3.18 Million
Q3 2020

Nov 16, 2020

SELL
$19.07 - $29.61 $1.89 Million - $2.94 Million
-99,359 Reduced 37.13%
168,223 $4.22 Million
Q2 2020

Aug 14, 2020

BUY
$23.21 - $31.43 $6.21 Million - $8.41 Million
267,582 New
267,582 $7.23 Million

Others Institutions Holding BNR

# of Institutions
1
Shares Held
21.2K
Call Options Held
0
Put Options Held
0

About Burning Rock Biotech Ltd


  • Ticker BNR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 105,188,000
  • Market Cap $642M
  • Description
  • Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and p...
More about BNR
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.